Episode 32 — Menstrual Cycles, Type 1 Diabetes, and the Gender Gap in Care

In this episode

The menstrual cycle affects roughly half of people with type 1 diabetes, yet it remains largely invisible in clinical guidelines, research literature, and algorithm design. Women report predictable patterns of insulin resistance in the days before their period, increased hypoglycaemia risk when bleeding starts, and intense frustration managing glucose levels that swing widely despite doing everything right.

Dr Cecilia Nobili, a physician-researcher living with type 1 diabetes herself, bridges the gap between lived experience and clinical evidence. Her observational study of 170 women explores how different insulin delivery systems handle monthly hormonal shifts, which phases create the biggest management burden, and why this represents a genuine gender gap in diabetes care.

The menstrual cycle roadmap

• Early follicular phase (days 1–7): Bleeding starts, oestrogen rises, progesterone drops — insulin sensitivity increases sharply, creating elevated hypoglycaemia risk if insulin doses are not reduced quickly.
• Mid follicular phase (days 8–12): Relatively stable glucose patterns for most women — the window where usual insulin strategies tend to work best.
• Periovulatory phase (days 13–15): Ovulation occurs around day 14 (varies by cycle length) — some women notice glucose changes here, but this phase is highly individual.
• Mid luteal phase (days 16–21): Progesterone begins climbing, insulin resistance starts building — early intervention tends to prevent worse highs later.
• Late luteal phase (days 22–28): Peak progesterone drives maximum insulin resistance — carb cravings intensify, time in range often drops, and frustration peaks.
• Not universal: Roughly 60% of women on MDI experience clinically significant glucose deterioration (5% or more drop in time in range), but patterns vary significantly — some women have minimal cycle impact, others experience dramatic swings.

Key themes

1. This is a gender gap in diabetes care

The menstrual cycle is largely absent from clinical guidelines, diabetes technology algorithms, and structured education programmes — despite affecting half the type 1 diabetes population monthly for decades. Women consistently report that menstrual cycle glucose management is harder than managing illness, yet intercurrent illness protocols are standard while menstrual cycle protocols largely do not exist.

2. Around 60% of women on MDI experience clinically significant deterioration

In Dr Nobili’s observational study of 170 women, 60% of those using multiple daily injections experienced a drop in time in range of 5% or more between the early follicular phase and the late luteal phase. This deterioration happens monthly, is predictable, and compounds over time.

3. AID systems reduce deterioration — but do not eliminate it

Hybrid closed-loop systems reduce the percentage of women experiencing clinically significant glucose deterioration from around 60% (on MDI) to 30–40% — even though these algorithms were not designed to account for menstrual cycles. This is a meaningful quality-of-life improvement. However, 30–40% of women on AID still experience meaningful deterioration, and many report frustrating hypoglycaemia in the early follicular phase when insulin sensitivity spikes.

4. Hypoglycaemia in the early follicular phase is the hidden burden

Dr Nobili found that many women ranked the early follicular phase — when bleeding starts and insulin sensitivity surges — as equally or more burdensome than the luteal phase. For women on AID systems that use recent total daily dose to set basal rates, the algorithm may deliver too much insulin when sensitivity returns, creating a hypoglycaemia surge just as the period starts.

5. Control-IQ shows the most stability across phases (observational data)

Observational data from Dr Nobili’s study suggests the Tandem t:slim Control-IQ system maintains relatively stable time in range across menstrual cycle phases, even without switching profiles. This likely reflects its design: Control-IQ does not heavily weight recent total daily dose, so it does not carry the luteal phase insulin resistance learning forward into the follicular phase. This is observation, not causation — but it is a clinically relevant pattern worth exploring with your team.

6. 780G and Omnipod 5 users may benefit from target adjustments at menstruation

Systems that prioritise recent total daily dose handle the luteal phase well but may create hypoglycaemia risk when bleeding starts. A practical approach: as soon as the period begins, raise the glucose target for three to four days to allow the algorithm time to recalibrate without causing lows. Discuss the specifics with your diabetes care team.

7. CamAPS FX boost function may be useful in the luteal phase

The CamAPS FX boost function increases insulin delivery by 30% without the algorithm learning from it — useful for temporary insulin resistance. Turning boost on during the mid and late luteal phases and turning it off when bleeding starts is a mechanism-based strategy worth exploring with your team.

8. MDI strategies: basal, carb ratios, or both

For women on injections, the luteal phase typically requires more insulin — but how you deliver it matters. Options include increasing long-acting insulin, strengthening carb ratios, or making correction factors more aggressive. The principle is to anticipate the change in the mid luteal phase rather than waiting until glucose is already high.

9. Pre-bolusing matters more during the luteal phase

Insulin resistance during the luteal phase means insulin acts more slowly relative to carbohydrate absorption. Pre-bolusing before meals becomes particularly important. Mixed meals — combining protein, fat, and vegetables with carbohydrates — slow absorption and better match insulin action.

10. One difficult day is not catastrophic

What matters is time in range averaged over weeks and months, not perfection every day. Reframing CGM data as information rather than judgement — “What happened? What’s the likely driver? What’s one tweak for next time?” — reduces the paralysis that comes from fear of imperfection.

11. Track your cycle and know your pattern

Normal cycle length is 28–35 days. Tracking cycle length, bleeding patterns, and glucose patterns across phases gives you the data to predict what is coming and adjust proactively. Know when your luteal phase tends to start, and when to expect bleeding.

12. Menstrual cycle tracking should be in the algorithm

Dr Nobili’s central point: menstrual cycle tracking apps already exist on smartphones. Linking these apps to AID algorithms is technically straightforward compared to the machine learning and fully closed-loop systems presented at diabetes conferences. Until this happens, the burden falls entirely on women to manually compensate for what the algorithm could be doing automatically.

Practical exploration checklist

Tracking and preparation

• Track cycle length (normal: 28–35 days) and note if bleeding is earlier or later than expected
• Review CGM data across two to three cycles to identify your personal glucose pattern
• Mark key phases in your calendar: mid luteal (day 16–18), late luteal (day 22–28), early follicular (when bleeding starts)

General principles

• Act proactively in the mid luteal phase (day 16–18) rather than waiting for highs to appear
• Reverse all adjustments when bleeding starts to reduce hypoglycaemia risk
• Accept that three to five difficult days per month is normal — one difficult day is not catastrophic
• Discuss patterns with your diabetes team — menstrual cycles should be part of routine clinic conversations

About the guest

Dr Cecilia Nobili is a pediatric diabetology resident in Turin, Italy, and a physician-researcher living with type 1 diabetes. Diagnosed at age 25 during the COVID-19 lockdown, she transformed her personal experience with trial-and-error diabetes management into clinical and research expertise. Dr Nobili leads a multi-centre observational study examining how menstrual cycles impact glucose control across different insulin delivery systems, funded by a Breakthrough T1D research grant. She is a graduate of the Spare Science School and an advocate for integrating menstrual cycle management into diabetes technology algorithms and clinical guidelines.

• LinkedIn profile

Related episodes

• Episode 31 — Pregnancy and Type 1 Diabetes (Prof. Eleanor Scott)
• Episode 33 — Exercise for females with type 1 diabetes (Prof. Jane Yardley)
• Episodes 1–6 — AID Systems Guide
• Episodes 10–12 — CGM Series
• Episode 30 — Diabetotech: Educating on Algorithms